Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbott laboratories d.o.o. - natrijev reviparinat - raztopina za injiciranje - natrijev reviparinat 1432 anti-xa i.e. / 0,25 ml - reviparin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbott laboratories d.o.o. - natrijev reviparinat - raztopina za injiciranje - natrijev reviparinat 3436 anti-xa i.e. / 0,6 ml - reviparin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

abbott laboratories d.o.o. - natrijev reviparinat - raztopina za injiciranje - natrijev reviparinat 5726 anti-xa i.e. / 1 ml - reviparin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

momaja s.r.o. - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 125 µg / 1 vpih - flutikazon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

momaja s.r.o. - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 250 µg / 1 vpih - flutikazon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

clinres farmacija d.o.o. - ekstrakt plodu palmeta - kapsula, mehka - ekstrakt plodu palmeta 320 mg / 1 kapsula - plod palmeta

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

clinres farmacija d.o.o. - ekstrakt plodu palmeta - kapsula, mehka - ekstrakt plodu palmeta 320 mg / 1 kapsula - plod palmeta

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - drugi antineoplastiki - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Evropska unija - slovenščina - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.